Arsenic risk assessment. by Smith, A H et al.
-9
conformationally restricted structural probes.
Mol Pharmacol 33:120-126 (1988).
3. McKinney JD, Korach KS, McLachlan JA.
Detoxification of polychlorinated biphenyls.
Lancet 335:222-223 (1990).
4. Bergman A, Klasson-Wehler E, Kuroki H.
Selective retention of hydroxylated PCB
metabolites in blood. Environ Health
Perspect 102:464-469 (1994).
Human Toxicity of PBDDs and
PBDFs
The brillant literature review and health
risk assessment by Mennear and Cheng-
Chung, "Polybrominated Dibenzo-p-diox-
ins and Dibenzofurans: Literature Review
and Health Assessment" [EHP 102(suppl
1):265-274], states that "reports ofhuman
toxicity associated with exposure to
PBDDs and PBDFs were not found" (p.
272). In fact, in their review, no references
are discussed or quoted regarding human
studies.
Two papers have been published on the
human toxicology ofthese compounds. The
first (1) is a recent report, previously pre-
sented at the Dioxin '90 Congress (2), about
a chemist who was exposed to 2,3,7,8,-
tetrabromodibenzodioxin (TBDD) and to
2,3,7,8-tetrachlorodibenzodioxin (TCDD)
in March and September 1956, respective-
ly, when synthesizing these chemicals. The
chemist was defined as "in good health" in
1990, when determinations of chlorinated
and brominated dioxins and dibenzofurans
were performed on whole blood. High
concentrations of several congeners were
detected, and the results were used to dis-
cuss the half-life of the chemicals in
humans. The subject presented a mild
chloracne after an unspecified time from
his exposure to bromodixoins in March,
suggesting that TBDD could produce skin
effects as chlorodioxins. Other more rele-
vant symptoms occurred after the exposure
to TCDD in September, and the patient
was hospitalized for a short period.
The second was a study of subjects
exposed to PBDDs and PBDFs as a result
of working at a BASF factory in etrusion
blending of polybutyleneterphthalate with
decarbromodiphenyl ether, used as a flame
retardant. The intensity of exposure was
determined in 1989 through air monitor-
ing (3). The paper presents blood levels of
2,3,7,8,-TBDF and TBDD and of total
congener profiles for some exposed work-
ers and the results of a comparison of sev-
eral immunological tests in a population of
exposed versus a population of unexposed
deriving from the same working cohort.
Workers had detectable blood levels of
TBDD and TBDF; half-life estimates of
these chemicals are presented. The results
of immunological tests were described as
"not adversely impacted at these burdens
of PBDFs and PBDDs," even though the
results ofseveral tests showed a correlation
with exposure, and in the subject having
the highest blood levels of PBDFs and
PBDDs, immunological changes were
quite relevant. The authors stated that clin-
ical examination did not reveal "skin
lesions consistent with an acnegenic
response.
It should be stressed that the results of
the two quoted articles do not change the
conclusions of Mennear and Cheng-
Chung on the health risks of PBDDs and
PBDFs. However, slightly different sugges-
tions for future research can be derived.
Human populations have been or are
exposed to these chemicals because oftheir
use in several work processes involving
flame retardants, environmental exposures
(mainly due to municipal incinerators), or
because of accidents due to thermal de-
composition of flame retardants. These
exposed human populations can be suit-
able, at least in theory, for toxicological
and epidemiological observations.
Enzo Merler
Eva Buiatti
Centre for the Study and Prevention of
Cancer
Florence, Italy
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Arsenic Risk Assessment
A commentary highly critical oftwo ofour
published studies was recently published in
EnvironmentalHealth Perspectives (Carlson-
Lynch et al., 102:354-356). One of our
papers examines the epidemiological evi-
dence for a methylation threshold for inor-
ganic arsenic and concludes that there is no
consistent evidence to support the hypoth-
esis ofsuch a threshold in humans (1). The
second paper critiqued by Carlson-Lynch
et al. estimates the human cancer risks of
arsenic at internal sites (lung, liver, kidney,
and bladder) using linear extrapolation
from Taiwanese data (2). Carlson-Lynch et
al. contend that the analyses conducted in
our studies are flawed and that the conclu-
sions reached in our publications are erro-
neous, rendering them unsuitable for use
by the EPA in risk assessment.
Whether or not our studies are used by
the EPA for risk assessment is oflittle con-
cern to us, but we are certainly concerned
about statements that they are flawed.
Careful examination will show that all of
the major points raised in the commentary
are either incorrect or have no valid basis.
We would like to respond to the criticisms
made, point by point, in the order present-
ed, beginning with the methylation paper
(1).
Critique: The average arsenic exposures
in almost all of the studies analyzed were
too low to observe methylation saturation.
Response: The commentators base this
statement on three issues. First, the authors
state that evidence from an experimental
study (ofonly four human volunteers each
receiving only one dose level) suggests that
methylation would be completely saturated
at exposures greater than 500 pg/day (3).
However, at the highest oral dose in this
study, 1000 pg/day, the amount ofurinary
arsenic in the inorganic form was only
26%, hardly demonstrating methylation
saturation even at this level. Buchet et al.
(3) state in their paper that "speciation of
the arsenic metabolites in urine indicated
that the arsenic methylation capacity ofthe
human body was not yet saturated, even
with an oral daily dose of 1000 pg As."
The evidence of any metabolic saturation
from this study is not conclusive. Each of
four arsenic dosing levels was assigned to a
different individual subject, making it
impossible to differentiate interindividual
differences in methylation efficiency from
dose-dependent effects that might apply to
a general population.
Second, the authors state that we ana-
lyzed only two groups with average urinary
arsenic levels at or above 190 pg/I, which
theyhypothesize corresponds to the concen-
tration above which methylation saturation
occurs. This statement obscures the fact that
1) the two groups combined had a total of
35 people, 2) our analysis ofavailable indi-
vidual data (see Figure 2 of our paper)
included 14 persons with urinary arsenic
levels >190 pg/l. No trend ofhigher relative
proportions ofunmethylated arsenic is sug-
gested for those 14 individuals.
Third, the authors state: ". . . a regres-
sion analysis on the individual data within
the Yamauchi et al. [4] population was bor-
derline significant atp = 0.10. . ." (p. 354).
However, this was just one of nine regres-
sion analyses we presented. The slopes were
positive in four (including the Yamauchi
study) but negative in five (1: Table 9).
As a matter of interest, in our more
recent studies ofchronically exposed popu-
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nations in the United States and Chile, we
have urinary speciation data for over 100
individuals exposed to average levels well
above 1000 pg As/day and ranging above
2000 pg/day with no evidence ofmethyla-
tion saturation even at these levels. Our
study in Nevada of 18 chronically exposed
individuals also found no evidence of
methylation saturation, even with an aver-
age estimated intake of2260 pgAs/day (5).
If a methylation threshold for arsenic
does exist, the epidemiological and experi-
mental evidence suggest that it must be at
exposure levels well above 2000 pg/day,
making it completely irrelevant to usual
human exposures and adverse health out-
comes.
Critique We used urinary arsenic con-
centrations from grab samples as the basis
for evaluating methylation capacity. How-
ever, the proportion of inorganic arsenic
excreted in the urine varies with time; thus
an individual grab sample is not represen-
tative of the degree of methylation that is
occurring.
Response This concern would apply to
small studies ofshort-term exposures, such
as those of experimental studies ofhuman
volunteers or incidents of accidental or
self-induced poisoning. Our critics again
cite as an example Buchet et al. (3), where
volunteers ingested a single daily dose of
arsenic for only five days, resulting in an
elimination profile with varying propor-
tions of the three urinary arsenic species
over the time period following ingestion.
However, for chronically exposed popula-
tions ingesting arsenic on a regular daily
basis, grab samples do give a representative
picture when averaged over the whole
group. For example, grab samples taken
from a large number ofpeople should give
the same methylation picture as 24- or 48-
hour samples (which our critics claim are
appropriate measurements) from randomly
selected subpopulations. It should be noted
that the epidemiological goal is often char-
acterizations of the group, and not precise
characterization of each individual. For
example, epidemiological studies frequent-
ly use one or two casual blood pressure
readings on individuals to characterize
groups, rather than 24-hour monitoring of
each person.
The following are points raised in criti-
cism of our cancer risk assessment paper
(2):
Critique: In deriving risk estimates
associated with arsenic exposure using lin-
ear regression, Smith et al. assumed that
the arsenic intake of the population was
zero. This assumption would artificially
increase the slope ofthe exposure-response
curve.
Response Relative to the exposed popu-
lations, the intake of the control popula-
tions was virtually zero. Nonetheless, exami-
nation of the graphs in Figure 1 of our
paper would show that the dose-
response slopes would actually increase
rather than decrease ifone assumed a higher
exposure for the control population.
Critique: Smith et al. did not discuss
the implications of detoxification in esti-
mating potential risks from low-level expo-
sures typical ofthe U.S. population.
Response: We did. A whole section of
our paper is devoted to it: "Is There a
Threshold?" Table 4 ofour paper presents
human methylation data.
Critique: Smith et al. do not consider
key uncertainties in the use of the Taiwan
data in their analysis. Reference is then
made to fluorescent humic substances in
Taiwanese drinking water.
Response: We have discussed this topic
in detail in another paper published by our
group (6) which we referenced in our
methylation article. In brief, there is little,
if any, valid evidence to support the claim
that humic substances contribute to
increased cancer occurrence in the arsenic-
endemic areas ofTaiwan.
Critique: We do not address the differ-
ences between the Taiwanese and U.S.
populations that would reduce the accura-
cy of using exposure-response data from
Taiwan for U.S. populations. We then
make reference to protein and methionine
intake.
Response: We did. A paragraph in the
section titled "Risk Estimation for the U.S.
Population" addresses this issue. For exam-
ple, in reference to protein deficiency, we
state: "If nutritionally inadequate diets
among the Taiwanese population exposed
to arsenic made them more susceptible to
the carcinogenic effects of arsenic, the
extrapolated risk estimates for the average
U.S. population would be too high" (2:
264). However, a reanalysis ofthe data pre-
sented in the paper referenced by our critics
(7) shows that by current standards the
Taiwanese intake of protein and methio-
nine was adequate (8).
Carlson-Lynch et al. further claim that
our exposure parameters in terms ofdrink-
ing water intake in Taiwan were too low.
We would merely note that we used pub-
lished EPA estimates of Taiwanese drink-
ing water intake (9). If one used higher
estimates, then cancer risk estimates for
the U.S. would indeed be a little lower.
However, the estimate of 4.5 liters of
arsenic-containing water per day that they
refer to comes from a speculative EPA staff
discussion with virtually no data to sup-
port it (10). In our view, the previous esti-
mate of 3.5 liters/day has just as much
plausibility for an all-year average for
males in a warm, but temperate, climate.
However, it is a moot point since thiSvanl-
able has only a small effect on risk esti-
mates.
Finally, in the brief paragraph of the
article not devoted to criticism ofour stud-
ies, the authors state that mechanistic or
more refined epidemiological studies are
needed to assess the relationship between
internal cancers and arsenic ingestion. On
this we can agree. They then cite as an
example an article by Guo et al. (11).
(Note: We have been informed that C.J.
Chen was not one ofthe authors as cited by
Carlson-Lynch et al., and that the paper
will be published in Journal ofGeological
Chemistry and Health, not Science and
Technology Letters). Since this interesting
article is in press and may not be available
at the time this letter is published, we will
note that it contains no mechanistic data.
Furthermore, it is an ecological study
which hardly qualifies as a "refined epi-
demiological study." In addition, the Guo
et al. paper uses a highly unusual form of
regression analysis whose validity has not
been established. Only well-designed epi-
demiological studies with individual expo-
sure data will identify the true dose-
response relationship between inorganic
arsenic ingestion and the risk of internal
cancers. At the present point in time, we
know ofno mechanistic data, nor firm epi-
demiological data, which allow one to con-
clude that the relationship between arsenic
ingestion and cancer is sublinear, let alone
confirm the existence ofa threshold.
In conclusion, an evaluation of the
commentary written by Carlson-Lynch et
al. demonstrates that none ofthe criticisms
is valid. It seems unfortunate that we were
not invited to comment at the time of its
publication.
Allan H. Smith
Mary Lou Biggs
Claudia Hopenhayn-Rich
School ofPublic Health
University ofCalifornia, Berkeley
David Kalman
School ofPublic Health
and CommunityMedicine
University ofWashington
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Response to Smith et al.
Smith et al.'s criticisms ofour commentary
in EHP(102:354-356) fall into four gener-
al categories: arsenic methylation and detox-
ification; the recalculation of the slope fac-
tor for ingested arsenic; differences between
U.S. and Taiwanese populations; and recent
epidemiological analyses. As discussed
below, we stand by our earlier conclusion
that the dose-response relationship for
arsenic carcinogenicity is likely to be nonlin-
ear, and we feel that there is no basis for dis-
missing the methylation saturation hypothe-
sis as one possible explanation for nonlinear-
ity. We offer the following response to
Smith et al.'s criticisms.
Arsenic methylation: We acknowledge
that the issue of arsenic methylation and
detoxification is complex; however, we
believe that the methodological limitations
we observed in the Hopenhayn-Rich et al.
(1) article on arsenic methylation weaken
their argument that human studies do not
support a methylation threshold hypothe-
sis for arsenic. Moreover, we call readers'
attention to several recent studies that sug-
gest that percent inorganic arsenic in urine
is not as sensitive an indicator ofthe satu-
ration ofthe methylation pathway as is the
ratio of the percentage of urinary metabo-
lites, MMA to DMA. Hughes et al. (2)
demonstrated an increase in the relative
percentage ofMMA to DMA (per admin-
istered dose of arsenic) excreted in the
urine ofmice, with increase in dose. In sin-
gle oral doses ranging from 0.5 to 5000
pg/kg, the ratio of MMA to DMA
increased by approximately a factor of 10
from the lowest to the highest group. The
relative percent ofinorganic arsenic bound
to tissue also increased with dose. The
authors propose that inorganic arsenic
binds to macromolecules and does not
appear in urine until the binding becomes
saturated. Therefore, inorganic arsenic is
not as sensitive an indicator of saturation
of the methylation pathway as is the con-
centration of methylated metabolites.
Similarly, in an epidemiological study of
humans exposed to elevated levels of
arsenic in drinking water in Mexico, Del
Razo et al. (3) report that the MMA:DMA
ratio in urine was significantly increased in
the study group by a factor of 2.4 times
relative to that in the control population.
In another epidemiological investigation of
increased levels ofarsenic in drinking water
in northeast Taiwan, Froines (4) observed
a statistical increase of 1.5 times in the
ratio of percentages of urinary MMA:
DMA in the exposed population relative to
the controls.
In our commentary, we stated that
Smith et al. (5) did not discuss the implica-
tions ofdetoxification in estimating poten-
tial risks from low-level exposures typical
of the U.S. population. To be more pre-
cise, we should have stated that although
Smith et al. briefly discussed methylation,
they neglected to adequately consider some
of the evidence that suggests there may be
a saturation level for the methylation reac-
tion, and therefore discounted the role of
detoxification in the dose-response rela-
tionship for arsenic carcinogenicity.
Smith et al. refer to studies in Chile
and Nevada which further support their
position regarding a lack of evidence for
saturation ofthe methylation pathway. We
recommend that these studies, as well as
other published data, be reviewed to see
whether MMA:DMA ratios change, on an
individual subject basis, with increasing
dose.
Issues concerning the recalculation ofthe
slopefactor: As Smith et al. have noted, we
incorrectly stated in our original commen-
tary that assuming a zero arsenic intake for
the control population would artificially
increase the slope ofthe exposure-response
curve. By assuming a zero intake for the
control population, Smith et al. did indeed
calculate a shallower slope, using a simple
linear regression, than would have been
calculated if the control population alone
had been assumed to have increased arsenic
exposure (and all other assumptions and
data points remained the same). We
should have stated that a more accurate
representation of the arsenic exposure for
all exposure groups, including careful
considerations of background dietary
arsenic intake and water consumption rates
in both exposed and control groups, as
well as the use of a more appropriate
dose-response model, would result in a sig-
nificantly decreased cancer slope factor
(CSF) and lower risks.
Background levels ofarsenic in the diet
should be considered as part ofexposure in
all groups, since elevated levels ofinorganic
arsenic have been shown to be present in
the food supply in Taiwan. Recent analyses
have suggested that the actual amount of
inorganic arsenic in the Taiwanese diet
may range from 62 to 290 pg per day (6).
Thus, dietary intake of arsenic in control
populations is unlikely to be "virtually
zero," as Smith et al. have suggested, and
estimates of dietary arsenic should be
added to all exposure groups, including the
control group.
As an example of the impact of back-
ground arsenic intake on estimates ofcan-
cer risk, Yost et al. (6) have shown that
EPA's current CSF for arsenic, calculated
using a linearized multistage model, would
be lowered from 1.75 to as little as 0.13
kg-day/mg by correcting for background
dietary sources of inorganic arsenic. Had
Smith et al. (5) used these estimates of
dietary arsenic intake in their analyses, an
overall decrease in calculated risks for
internal cancers would have been expected.
However, this lowered risk would be
reflected in Smith et al. (5) as a change in
the intercept, but not the slope, of the
exposure-response curve because they used
simple linear regression to model total (as
opposed to excess) mortality.
Water ingestion rates also can signifi-
cantly affect total arsenic exposure and the
calculation of cancer slope factors. As dis-
cussed in our commentary, EPA has
recently approved an RfD for arsenic based
on Taiwanese data and a water consump-
tion rate of4.5 1/day for males and females
(7). While it is true that EPAhad previous-
ly estimated Taiwanese water intake to be
3.5 1/day for males and 2 1/day for females
(8), the characterization by Smith et al.
that the more recent estimate of4.5 1/day
comes from "a speculative EPA staff dis-
cussion with virtually no data to support
it" is inappropriate. Abernathy and his col-
leagues considered discussions of water
consumption rates with several individuals
from a Taiwanese Blackfoot treatment cen-
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